Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest update is out from Inhibrx Biosciences Inc ( (INBX) ).
Inhibrx Biosciences, Inc. held its 2025 Annual Meeting of Stockholders on May 28, 2025, in a virtual format. During the meeting, a quorum of approximately 79% of eligible shares was present. Key outcomes included the election of Jon Faiz Kayyem, Ph.D., and Kristiina Vuori, M.D., Ph.D., as Class I Directors to serve until the 2028 Annual Meeting, and the ratification of BDO USA, P.C. as the independent registered public accounting firm for the year ending December 31, 2025.
Spark’s Take on INBX Stock
According to Spark, TipRanks’ AI Analyst, INBX is a Neutral.
Inhibrx Biosciences Inc’s overall stock score is primarily impacted by its poor financial performance, characterized by revenue and cash flow challenges and high leverage. While technical indicators show some positive momentum, potential overbought conditions and high financial risk weigh heavily. Valuation suggests potential undervaluation, but caution is advised due to underlying financial issues.
To see Spark’s full report on INBX stock, click here.
More about Inhibrx Biosciences Inc
Average Trading Volume: 115,550
Technical Sentiment Signal: Sell
Current Market Cap: $190.1M
Learn more about INBX stock on TipRanks’ Stock Analysis page.